Results 61 to 70 of about 12,905,954 (250)
SerpinA3 acts as an endogenous TGF‐β receptor antagonist that binds to the extracellular domain of TGFR‐1, thereby preventing TGFR‐1–TGFR‐2 complex formation. This receptor‐level blockade suppresses TGF‐β/Smad2/3 signaling, attenuates cardiac fibroblast activation, and extracellular matrix deposition, and ultimately alleviates pressure overload–induced
Hui Wang +9 more
wiley +1 more source
Matrix stiffness directs mesenchymal stem cell lineage commitment through PIEZO1‐dependent activation of the SP1/STC2 pathway. Stiff matrices favor osteogenesis and suppress adipogenesis, whereas the loss of PIEZO1 function impairs early bone formation. STC2 retains lineage‐regulatory activity even when PIEZO1 is inactive.
Shuo Zhang +12 more
wiley +1 more source
study on the effects of two different regimens of recombinant human growth hormone therapy on the bone mineral density of patients with growth hormone ...
Tatò L. +4 more
core +1 more source
As a novel adipose‐derived neurotrophic factor, Follistatin‐like 1 is endocytosed by sympathetic neurons primarily via tropomyosin‐related kinase B. This process promotes sympathetic innervation in adipose tissue and norepinephrine release, leading to white adipose tissue browning, enhanced thermogenesis, and anti‐obesity effects in mice.
Xiao‐Wei Jia +13 more
wiley +1 more source
OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li +11 more
wiley +1 more source
The influence of growth hormone deficiency on bone health and metabolism
Growth hormone (GH) is a key peptide hormone in the regulation of bone metabolism, through its systemic and paracrine action mediated directly as well as by insulin-like growth factor-1 (IGF-1).
Jakub Wydra +3 more
core +1 more source
Improvement of growth and food utilization by human recombinant growth hormone in uremia
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation. Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Mehls, Otto +5 more
openaire +2 more sources
Guided by pharmacophore modeling and molecular docking, aryl hydrocarbon receptor (AHR)‐responsive carbon dots were synthesized. They bind directly to AHR and expand gut‐resident regulatory T (Treg) cells. Treg‐derived C‐C motif chemokine ligand 1 (CCL1) enhances macrophage efferocytosis, creating a pro‐regenetative niche that promotes colonic mucosal ...
Zilu Zhu +6 more
wiley +1 more source
In the post‐stroke brain, Foxa2 induces the transcriptional upregulation of Nrsn1 in NSCs. Nrsn1 functionally couples with Smarcc1, modulating its nuclear availability and protein abundance, thereby influencing Smarcc1‐associated regulatory programs linked to neuronal lineage commitment. Through this coupling, Nrsn1 promotes the differentiation of NSCs
Ruolin Zhang +18 more
wiley +1 more source
Growth hormone (GH) provocation tests and the response to GH treatment in GH deficiency [PDF]
Objective: To identify factors, particularly the growth hormone (GH) provocation test result, affecting growth response to GH treatment in children with GH deficiency (GHD).Subjects: A total of 337 prepubertal GHD patients aged,10 years from the UK ...
Hindmarsh, PC, Dunger, DB, Cole, TJ
core

